Test Code MDC2 Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Ordering Guidance
Multiple neurological phenotype-specific autoimmune/paraneoplastic evaluations are available. For more information as well as phenotype-specific testing options, see Autoimmune Neurology Test Ordering Guide.
When more than one evaluation is ordered on the same order number the duplicate will be canceled.
For a list of antibodies performed with each evaluation, see Autoimmune Neurology Antibody Matrix.
Necessary Information
Provide the following information:
-Relevant clinical information
-Ordering healthcare professional’s name, phone number, mailing address, and e-mail address
Specimen Required
Patient Preparation: For optimal antibody detection, collect specimen before starting immunosuppressant medication, corticosteroids, or intravenous immunoglobulin treatment.
Container/Tube: Sterile vial
Preferred: Collection vial number 1
Acceptable: Any collection vial
Specimen Volume: 4 mL
Forms
If not ordering electronically, complete, print, and send a Neurology Specialty Testing Client Test Request (T732) with the specimen.
Secondary ID
606193Useful For
Evaluating patients with suspected paraneoplastic or other autoimmune movement disorders including patients with ataxia, brainstem encephalitis, chorea, dyskinesias, myoclonus, and parkinsonism using spinal fluid specimens
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| MDCI | Movement Disorder Interp, CSF | No | Yes |
| AMPCC | AMPA-R Ab CBA, CSF | No | Yes |
| AMPHC | Amphiphysin Ab, CSF | No | Yes |
| AGN1C | Anti-Glial Nuclear Ab, Type 1 | No | Yes |
| ANN1C | Anti-Neuronal Nuclear Ab, Type 1 | No | Yes |
| ANN2C | Anti-Neuronal Nuclear Ab, Type 2 | No | Yes |
| ANN3C | Anti-Neuronal Nuclear Ab, Type 3 | No | Yes |
| APBIC | AP3B2 IFA, CSF | No | Yes |
| CS2CC | CASPR2-IgG CBA, CSF | No | Yes |
| CRMC | CRMP-5-IgG, CSF | No | Yes |
| DPPCC | DPPX Ab CBA, CSF | No | Yes |
| GABCC | GABA-B-R Ab CBA, CSF | No | Yes |
| GD65C | GAD65 Ab Assay, CSF | Yes | Yes |
| GFAIC | GFAP IFA, CSF | No | Yes |
| GRFIC | GRAF1 IFA, CSF | No | Yes |
| IG5CC | IgLON5 CBA, CSF | No | Yes |
| ITPIC | ITPR1 IFA, CSF | No | Yes |
| KLHCC | KLHL11-IgG CBA, CSF | Yes | Yes |
| LG1CC | LGI1-IgG CBA, CSF | No | Yes |
| MA2EC | Ma2 Ab ELISA, CSF | Yes | Yes |
| GL1IC | mGluR1 Ab IFA, CSF | No | Yes |
| GL5IC | mGluR5 Ab IFA, CSF | No | Yes |
| NCDIC | Neurochondrin IFA, CSF | No | Yes |
| NIFIC | NIF IFA, CSF | No | Yes |
| NMDCC | NMDA-R Ab CBA, CSF | No | Yes |
| PDEIC | PDE10A Ab IFA, CSF | No | Yes |
| PCTRC | Purkinje Cell Cytoplasmc Ab Type Tr | No | Yes |
| PCA1C | Purkinje Cell Cytoplasmic Ab Type 1 | No | Yes |
| PCA2C | Purkinje Cell Cytoplasmic Ab Type 2 | No | Yes |
| SP5IC | Septin-5 IFA, CSF | No | Yes |
| SP7IC | Septin-7 IFA, CSF | No | Yes |
| T46IC | TRIM46 Ab IFA, CSF | No | Yes |
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AGNBC | AGNA-1 Immunoblot, CSF | No | No |
| AINCC | Alpha Internexin CBA, CSF | No | No |
| AMPIC | AMPA-R Ab IF Titer Assay, CSF | No | No |
| AMIBC | Amphiphysin Immunoblot, CSF | No | No |
| AN1BC | ANNA-1 Immunoblot, CSF | No | No |
| AN2BC | ANNA-2 Immunoblot, CSF | No | No |
| DPPTC | DPPX Ab IFA Titer, CSF | No | No |
| GABIC | GABA-B-R Ab IF Titer Assay, CSF | No | No |
| GRFCC | GRAF1 CBA, CSF | No | No |
| GRFTC | GRAF1 IFA Titer, CSF | No | No |
| IG5TC | IgLON5 IFA Titer, CSF | No | No |
| ITPCC | ITPR1 CBA, CSF | No | No |
| ITPTC | ITPR1 IFA Titer, CSF | No | No |
| GL1TC | mGluR1 Ab IFA Titer, CSF | No | No |
| GL1CC | mGluR1 Ab CBA, CSF | No | No |
| NFHCC | NIF Heavy Chain CBA, CSF | No | No |
| NIFTC | NIF IFA Titer, CSF | No | No |
| NFLCC | NIF Light Chain CBA, CSF | No | No |
| NMDIC | NMDA-R Ab IF Titer Assay, CSF | No | No |
| PC1BC | PCA-1 Immunoblot, CSF | No | No |
| PCTBC | PCA-Tr Immunoblot, CSF | No | No |
| AN1TC | ANNA-1 Titer, CSF | No | No |
| AN2TC | ANNA-2 Titer, CSF | No | No |
| AN3TC | ANNA-3 Titer, CSF | No | No |
| APBCC | AP3B2 CBA, CSF | No | No |
| CRMTC | CRMP-5-IgG Titer, CSF | No | No |
| GFACC | GFAP CBA, CSF | No | No |
| GFATC | GFAP IFA Titer, CSF | No | No |
| NCDCC | Neurochondrin CBA, CSF | No | No |
| NCDTC | Neurochondrin IFA Titer, CSF | No | No |
| PC1TC | PCA-1 Titer, CSF | No | No |
| PC2TC | PCA-2 Titer, CSF | No | No |
| PCTTC | PCA-Tr Titer, CSF | No | No |
| PDETC | PDE10A Ab IFA Titer, CSF | No | No |
| SP5CC | Septin-5 CBA, CSF | No | No |
| SP5TC | Septin-5 IFA Titer, CSF | No | No |
| SP7CC | Septin-7 CBA, CSF | No | No |
| SP7TC | Septin-7 IFA Titer, CSF | No | No |
| T46CC | TRIM46 Ab CBA, CSF | No | No |
| T46TC | TRIM46 Ab IFA Titer, CSF | No | No |
| AGNTC | AGNA-1 Titer, CSF | No | No |
| K11TC | KLHL11 Ab IFA Titer, CSF | No | No |
| MP1BC | MAP1B Immunoblot, CSF | No | No |
| GL5CC | mGluR5 Ab CBA, CSF | No | No |
| GL5TC | mGluR5 Ab IFA Titer, CSF | No | No |
| APHTC | Amphiphysin Ab Titer, CSF | No | No |
| CRMWC | CRMP-5-IgG Western Blot, CSF | No | No |
| APBTC | AP3B2 IFA Titer, CSF | No | No |
Testing Algorithm
If the immunofluorescence assay (IFA) patterns suggest amphiphysin antibody, then the amphiphysin immunoblot and amphiphysin IFA titer will be performed at an additional charge.
If the IFA pattern suggests antiglial nuclear antibody (AGNA)-1, then the AGNA-1 immunoblot and AGNA-1 IFA titer will be performed at an additional charge.
If the IFA pattern suggests antineuronal nuclear antibody type 1 (ANNA-1), then the ANNA-1 immunoblot, ANNA-1 IFA titer, and ANNA-2 immunoblot will be performed at an additional charge.
If the IFA pattern suggests ANNA-2, then the ANNA-2 immunoblot, ANNA-2 IFA titer, and ANNA-1 immunoblot will be performed at an additional charge.
If the client requests or the IFA pattern suggests ANNA-3 antibodies, then the ANNA-3 IFA titer will be performed at an additional charge.
If the IFA pattern suggests adaptor protein 3 beta2 (AP3B2) antibodies, then the AP3B2 cell-binding assay (CBA) and AP3B2 IFA titer will be performed at an additional charge.
If the IFA patterns suggest collapsin response-mediator protein-5 (CRMP-5)-IgG, then the CRMP-5-IgG Western blot and CRMP-5-IgG IFA titer will be performed at an additional charge.
If the IFA pattern suggests Purkinje cytoplasmic antibody type 1 (PCA-1), then the PCA-1 IFA titer and PCA-1 immunoblot will be performed at an additional charge.
If the IFA pattern suggests PCA-Tr, then the PCA-Tr IFA titer and PCA-Tr immunoblot will be performed at an additional charge.
If the IFA pattern suggests PCA-2 antibody, then the PCA-2 IFA titer and MAP1B immunoblot will be performed at an additional charge.
If the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-receptor CBA result is positive, then the AMPA-receptor antibody IFA titer will be performed at an additional charge.
If the dipeptidyl-peptidase-like protein-6 (DPPX) antibody CBA result is positive, then the DPPX antibody IFA titer will be performed at an additional charge.
If the gamma-aminobutyric acid B (GABA-B)-receptor CBA result is positive, then the GABA-B-receptor antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests glial fibrillary acidic protein (GFAP) antibody, then the GFAP antibody CBA and GFAP antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests metabotropic glutamate receptor 1 (mGluR1) antibody, then the mGluR1 CBA and mGluR1 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests metabotropic glutamate receptor 5 (mGluR5) antibody, then the mGluR5 CBA and mGluR5 antibody IFA titer will be performed at an additional charge.
If the N-methyl-D-aspartate (NMDA)-receptor CBA result is positive, then the NMDA-receptor antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests GTPase regulator associated with focal adhesion kinase-1 (GRAF1) antibody, then the GRAF1 CBA and GRAF1 antibody IFA titer will be performed at an additional charge.
If the IgLON5 antibody CBA result is positive, then the IgLON5 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests inositol 1,4,5-trisphosphate receptor (ITPR1) antibody, then the ITPR1 CBA and ITPR1 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests neuronal intermediate filament (NIF) antibody, then the alpha internexin CBA, NIF heavy chain CBA, NIF light chain CBA, and NIF antibody IFA titer will be performed at an additional charge.
If the Kelch-like protein 11 (KLHL11) CBA result is reactive, then the KLHL11 antibody IFA titer will be performed at an additional charge.
If the IFA pattern suggests neurochondrin antibody, then the neurochondrin antibody CBA and neurochondrin IFA titer will be performed at an additional charge.
If the IFA pattern suggests septin-5 antibody, then the septin-5 CBA and septin-5 IFA titer will be performed at an additional charge.
If the IFA pattern suggests septin-7 antibody, then the septin-7 CBA and septin-7 IFA titer will be performed at an additional charge.
If the IFA pattern suggests tripartite motif-containing protein 46 (TRIM46) antibody, then the TRIM46 antibody CBA and TRIM46 IFA titer will be performed at an additional charge.
If the IFA pattern suggests phosphodiesterase 10A (PDE10A) antibody, then the PDE10A antibody IFA titer will be performed at an additional charge.
For more information see:
Autoimmune/Paraneoplastic Movement Disorder Evaluation Algorithm-Spinal Fluid
Central Nervous System Demyelinating Disease Diagnostic Algorithm
Method Name
AGN1C, AMPHC, ANN1C, ANN2C, ANN3C, APBIC, CRMC, GFAIC, GL1IC, GL5IC, GRFIC, ITPIC, NCDIC, NIFIC, PCA1C, PCA2C, PCTRC, PDEIC, SP5IC, SP7IC, T46IC, AGNTC, AMPIC, AN1TC, AN2TC, AN3TC, APHTC, CRMTC, DPPTC, GABIC, GFATC, GL1TC, GL5TC, GRFTC, IG5TC, ITPTC, K11TC, NCDTC, NIFTC, NMDIC, PC1TC, PC2TC, PCTTC, PDETC, SP5TC, SP7TC, T46TC: Indirect Immunofluorescence Assay (IFA)
AMPCC, CS2CC, DPPCC, GABCC, IG5CC, KLHCC, LG1CC, NMDCC, AINCC, APBCC, GFACC, GL1CC, GL5CC, GRFCC, ITPCC, NCDCC, NFHCC, NFLCC, SP5CC, SP7CC, T46CC: Cell Binding Assay (CBA)
MA2EC: Enzyme-Linked Immunosorbent Assay (ELISA)
CRMWC: Western Blot (WB)
GD65C: Radioimmunoassay (RIA)
AGNBC, AMIBC, AN1BC, AN2BC, MP1BC, PC1BC, PCTBC: Immunoblot (IB)
MDCI: Technical Interpretation
Reporting Name
Movement, Autoimm/Paraneo, CSFSpecimen Type
CSFSpecimen Minimum Volume
2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| CSF | Refrigerated (preferred) | 28 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Autoimmune movement disorders encapsulate a large and diverse group of neurologic disorders occurring either in isolation or accompanying more diffuse autoimmune encephalitic illnesses.
The full range of movement phenomena has been described, and, as they often occur in adults, many of the presentations can mimic neurodegenerative disorders, such as autoimmune chorea mimicking Huntington disease. Disorders may be ataxic, hypokinetic (parkinsonism), or hyperkinetic (myoclonus, chorea other dyskinetic disorders). Associated disorders may fall under the rubric of brainstem encephalitis.
The autoantibody targets are diverse and include neuronal surface proteins, such as leucine-rich, glioma-inactivated 1 (LGI1), as well as antibodies reactive with intracellular antigens (such as Purkinje cell cytoplasmic antibody-1 [PCA-1]) that are markers of a central nervous system process mediated by CD8+ cytotoxic T cells.
In some instances (such as PCA-1 autoimmunity), antibodies detected in serum and cerebrospinal fluid can be indicative of a paraneoplastic cause and may direct the cancer search. In other instances (such as 65-kDa isoform of glutamic acid decarboxylase [GAD65] autoimmunity), a paraneoplastic cause is very unlikely, and early treatment with immunotherapy may promote improvement or recovery.
Reference Values
|
Test ID |
Reporting name |
Methodology* |
Reference value |
|
MDCI |
Movement Disorder Interp, CSF |
Technical interpretation |
Interpretive report |
|
AMPCC |
AMPA-R Ab CBA, CSF |
CBA |
Negative |
|
AMPHC |
Amphiphysin Ab, CSF |
IFA |
Negative |
|
AGN1C |
Anti-Glial Nuclear Ab, Type 1 |
IFA |
Negative |
|
ANN1C |
Anti-Neuronal Nuclear Ab, Type 1 |
IFA |
Negative |
|
ANN2C |
Anti-Neuronal Nuclear Ab, Type 2 |
IFA |
Negative |
|
ANN3C |
Anti-Neuronal Nuclear Ab, Type 3 |
IFA |
Negative |
|
APBIC |
AP3B2 IFA, CSF |
IFA |
Negative |
|
CS2CC |
CASPR2-IgG CBA, CSF |
CBA |
Negative |
|
CRMC |
CRMP-5-IgG, CSF |
IFA |
Negative |
|
DPPCC |
DPPX Ab CBA, CSF |
CBA |
Negative |
|
GABCC |
GABA-B-R Ab CBA, CSF |
CBA |
Negative |
|
GD65C |
GAD65 Ab Assay, CSF |
RIA |
≤0.02 nmol/L |
|
GFAIC |
GFAP IFA, CSF |
IFA |
Negative |
|
GRFIC |
GRAF1 IFA, CSF |
IFA |
Negative |
|
IG5CC |
IgLON5 CBA, CSF |
CBA |
Negative |
|
ITPIC |
ITPR1 IFA, CSF |
IFA |
Negative |
|
KLHCC |
KLHL11-IgG CBA, CSF |
CBA |
Negative |
|
LG1CC |
LGI1-IgG CBA, CSF |
CBA |
Negative |
|
MA2EC |
Ma2 Ab ELISA, CSF |
ELISA |
Negative |
|
GL1IC |
mGluR1 Ab IFA, CSF |
IFA |
Negative |
|
GL5IC |
mGluR5 Ab IFA, CSF |
IFA |
Negative |
|
NCDIC |
Neurochondrin IFA, CSF |
IFA |
Negative |
|
NIFIC |
NIF IFA, CSF |
IFA |
Negative |
|
NMDCC |
NMDA-R Ab CBA, CSF |
CBA |
Negative |
|
PDEIC |
PDE10A Ab IFA, CSF |
IFA |
Negative |
|
PCTRC |
Purkinje Cell Cytoplasmc Ab Type Tr |
IFA |
Negative |
|
PCA1C |
Purkinje Cell Cytoplasmic Ab Type 1 |
IFA |
Negative |
|
PCA2C |
Purkinje Cell Cytoplasmic Ab Type 2 |
IFA |
Negative |
|
SP5IC |
Septin-5 IFA, CSF |
IFA |
Negative |
|
SP7IC |
Septin-7 IFA, CSF |
IFA |
Negative |
|
T46IC |
TRIM46 Ab IFA, CSF |
IFA |
Negative |
Reflex Information:
|
Test ID |
Reporting name |
Methodology* |
Reference value |
|
AGNBC |
AGNA-1 Immunoblot, CSF |
IB |
Negative |
|
AGNTC |
AGNA-1 Titer, CSF |
IFA |
<1:2 |
|
AINCC |
Alpha Internexin CBA, CSF |
CBA |
Negative |
|
AMPIC |
AMPA-R Ab IF Titer Assay, CSF |
IFA |
<1:2 |
|
APHTC |
Amphiphysin Ab Titer, CSF |
IFA |
<1:2 |
|
AMIBC |
Amphiphysin Immunoblot, CSF |
IB |
Negative |
|
AN1BC |
ANNA-1 Immunoblot, CSF |
IB |
Negative |
|
AN1TC |
ANNA-1 Titer, CSF |
IFA |
<1:2 |
|
AN2BC |
ANNA-2 Immunoblot, CSF |
IB |
Negative |
|
AN2TC |
ANNA-2 Titer, CSF |
IFA |
<1:2 |
|
AN3TC |
ANNA-3 Titer, CSF |
IFA |
<1:2 |
|
APBCC |
AP3B2 CBA, CSF |
CBA |
Negative |
|
CRMTC |
CRMP-5-IgG Titer, CSF |
IFA |
<1:2 |
|
CRMWC |
CRMP-5-IgG Western Blot, CSF |
WB |
Negative |
|
DPPTC |
DPPX Ab IFA Titer, CSF |
IFA |
<1:2 |
|
GABIC |
GABA-B-R Ab IF Titer Assay, CSF |
IFA |
<1:2 |
|
GFACC |
GFAP CBA, CSF |
CBA |
Negative |
|
GFATC |
GFAP IFA Titer, CSF |
IFA |
<1:2 |
|
GRFCC |
GRAF1 CBA, CSF |
CBA |
Negative |
|
GRFTC |
GRAF1 IFA Titer, CSF |
IFA |
<1:2 |
|
IG5TC |
IgLON5 IFA Titer, CSF |
IFA |
<1:2 |
|
ITPCC |
ITPR1 CBA, CSF |
CBA |
Negative |
|
ITPTC |
ITPR1 IFA Titer, CSF |
IFA |
<1:2 |
|
K11TC |
KLHL11 Ab IFA Titer, CSF |
IFA |
<1:2 |
|
MP1BC |
MAP1B Immunoblot, CSF |
IB |
Negative |
|
GL1CC |
mGluR1 Ab CBA, CSF |
CBA |
Negative |
|
GL1TC |
mGluR1 Ab IFA Titer, CSF |
IFA |
<1:2 |
|
GL5CC |
mGluR5 Ab CBA, CSF |
CBA |
Negative |
|
GL5TC |
mGluR5 Ab IFA Titer, CSF |
IFA |
<1:2 |
|
NCDCC |
Neurochondrin CBA, CSF |
CBA |
Negative |
|
NCDTC |
Neurochondrin IFA Titer, CSF |
IFA |
<1:2 |
|
NFHCC |
NIF Heavy Chain CBA, CSF |
CBA |
Negative |
|
NIFTC |
NIF IFA Titer, CSF |
IFA |
<1:2 |
|
NFLCC |
NIF Light Chain CBA, CSF |
CBA |
Negative |
|
NMDIC |
NMDA-R Ab IF Titer Assay, CSF |
IFA |
<1:2 |
|
PC1BC |
PCA-1 Immunoblot, CSF |
IB |
Negative |
|
PC1TC |
PCA-1 Titer, CSF |
IFA |
<1:2 |
|
PC2TC |
PCA-2 Titer, CSF |
IFA |
<1:2 |
|
PCTBC |
PCA-Tr Immunoblot, CSF |
IB |
Negative |
|
PCTTC |
PCA-Tr Titer, CSF |
IFA |
<1:2 |
|
PDETC |
PDE10A Ab IFA Titer, CSF |
IFA |
<1:2 |
|
SP5CC |
Septin-5 CBA, CSF |
CBA |
Negative |
|
SP5TC |
Septin-5 IFA Titer, CSF |
IFA |
<1:2 |
|
SP7CC |
Septin-7 CBA, CSF |
CBA |
Negative |
|
SP7TC |
Septin-7 IFA Titer, CSF |
IFA |
<1:2 |
|
T46CC |
TRIM46 Ab CBA, CSF |
CBA |
Negative |
|
T46TC |
TRIM46 Ab IFA Titer, CSF |
IFA |
<1:2 |
*Methodology abbreviations:
Cell-binding assay (CBA)
Enzyme-linked immunosorbent assay (ELISA)
Immunoblot (IB)
Indirect immunofluorescence assay (IFA)
Radioimmunoassay (RIA)
Western blot (WB)
Interpretation
A positive antibody result is consistent with a diagnosis of an autoimmune movement disorder.
A search for cancer may be indicated, depending on the antibody profile.
A trial of immune therapy may bring about improvement in neurological symptoms.
Method Description
Cell-Binding Assay:
Patient specimen is applied to a composite slide containing transfected and nontransfected EU90 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Klein CJ, Lennon VA, Aston PA, et al. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping. JAMA Neurol 2013;70[2]:229-234; package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN; FA_112d-1_A_UK_C13, 02/25/2019)
Indirect Immunofluorescence Assay:
The patient's specimen is tested by a standardized immunofluorescence assay that uses a composite frozen section of mouse cerebellum, kidney, and gut tissues. After incubation with the specimen and washing, fluorescein-conjugated goat-antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Specimens that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption.(Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4[5]:e385. Published 2017 Jul 18. doi:10.1212/NXI.0000000000000385)
Radioimmunoassay:
(125)I-labeled recombinant human antigens or labeled receptors are incubated with patient specimen. After incubation, anti-human IgG is added to form an immunoprecipitate. The amount of (125)I-labeled antigen in the immunoprecipitate is measured using a gamma-counter. The amount of gamma emission in the precipitate is proportional to the amount of antigen-specific IgG in the specimen. Results are reported as units of precipitated antigen (nmol) per liter of patient specimen.(Griesmann GE, Kryzer TJ, Lennon VA. Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Rose NR, Hamilton RG, eds. Manual of Clinical and Laboratory Immunology. 6th ed. ASM Press; 2002:1005-1012; Walikonis JE, Lennon VA. Radioimmunoassay for glutamic acid decarboxylase [GAD65] autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc. 1998;73[12]:1161-1166; Jones AL, Flanagan EP, Pittock SJ, et al. Responses to and outcomes of treatment of autoimmune cerebellar ataxia in adults. JAMA Neurol. 2015;72[11]:1304-1312. doi:10.1001/jamaneurol.2015.2378)
Western Blot:
Neuronal antigens extracted aqueously from adult rat cerebellum, full-length recombinant human collapsin response-mediator protein-5 (CRMP-5), or full-length recombinant human amphiphysin protein is denatured, reduced, and separated by electrophoresis on 10% polyacrylamide gel. IgG is detected autoradiographically by enhanced chemiluminescence.(Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49[2]:146-154; Dubey D, Jitprapaikulsan J, Bi H, et al. Amphiphysin-IgG autoimmune neuropathy: A recognizable clinicopathologic syndrome. Neurology. 2019;93[20]:e1873-e1880. doi:10.1212/WNL.0000000000008472)
Enzyme-Linked Immunosorbent Assay:
Ma2 antibodies are directed against their corresponding intracellular protein (PNMA2). The Ma2 autoantibody enzyme-linked immunosorbent assay (ELISA) is based on the principle of indirect ELISA that employs the ability of Ma2 autoantibodies to bind to antigenic protein (PNMA2) coated on the well surface of an ELISA plate. Detection of this bound antibody is accomplished using an antihuman secondary antibody that specifically recognizes the Fc region of the bound autoantibody. The secondary antibody is conjugated with alkaline phosphatase that enzymatically hydrolyzes a substrate molecule to produce an end product with a yellow color measurable at a wavelength of 405 nm. Controls and diluted samples are added in duplicate to coated plate wells and incubated for 2 hours, then washed extensively before adding the conjugated secondary antibody for an additional hour. After aspiration and washing, p-nitrophenyl phosphate substrate is added to each well and incubated for an additional hour before absorbance is measured at 405 nm.(Unpublished Mayo method)
Immunoblot for AGNA-1, amphiphysin, ANNA-1, ANNA-2, PCA-1, and PCA-Tr:
All steps are performed at room temperature (18 to 28° C) utilizing the EUROBlot One instrument. Diluted patient sample is added to test strips (strips containing recombinant antigen manufactured and purified using biochemical methods) in individual channels and incubated for 30 minutes. Positive samples will bind to the purified recombinant antigen and negative samples will not bind. Strips are washed to remove unbound antibodies and then incubated with anti-human IgG antibodies (alkaline phosphatase-labelled) for 30 minutes. The strips are again washed to remove unbound anti-human IgG antibodies and nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) substrate is added. Alkaline phosphatase enzyme converts the soluble substrate into a colored insoluble product on the membrane to produces a black band. Strips are digitized via picture capture on the EUROBlot One instrument and evaluated with the EUROLineScan software.(O'Connor K, Waters P, Komorowski L, et al. GABAA receptor autoimmunity: A multicenter experience. Neurol Neuroimmunol Neuroinflamm. 2019;6[3]:e552. doi:10.1212/NXI.0000000000000552)
Immunoblot for MAP1B:
Test strips are incubated with appropriately diluted sample, prepared to meet the assay's required end-dilution for each specimen type. Samples and controls are added directly to the strips, ensuring they are fully covered with dilution buffer, then mixed gently and incubated for 60 minutes at room temperature on a rocking platform. After incubation, the strips undergo a series of wash steps using diluted wash buffer, followed by a 30-minute incubation with a ready-to-use alkaline phosphatase-labeled IgG conjugate. The strips are washed again using the same procedure, then incubated with a ready-to-use substrate solution for 20 minutes at room temperature. The reaction is stopped by rinsing with distilled water through several wash cycles. Strips are then placed on absorbent material and allowed to dry fully, generally requiring at least two hours. Results are interpreted only after the strips have dried completely, and dried strips are stored protected from light.(Package insert: PCA-2 line assay. ravo Diagnostika GmbH; 05/2023)
Day(s) Performed
Profile tests: Monday through Sunday; Reflex tests: Varies
Performing Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
86255 x28
83516
86341
0432U
84182 AGNBC (if appropriate)
86256 AGNTC (if appropriate)
86255 AINCC (if appropriate)
86256 AMPIC (if appropriate)
86256 APHTC (if appropriate)
84182 AMIBC (if appropriate)
84182 AN1BC (if appropriate)
86256 AN1TC (if appropriate)
84182 AN2BC (if appropriate)
86256 AN2TC (if appropriate)
86256 AN3TC (if appropriate)
86255 APBCC (if appropriate)
86256 CRMTC (if appropriate)
84182 CRMWC (if appropriate)
86256 DPPTC (if appropriate)
86256 GABIC (if appropriate)
86255 GFACC (if appropriate)
86256 GFATC (if appropriate)
86255 GRFCC (if appropriate)
86256 GRFTC (if appropriate)
86256 IG5TC (if appropriate)
86255 ITPCC (if appropriate)
86256 ITPTC (if appropriate)
86256 K11TC (if appropriate)
84182 MP1BC (if appropriate)
86255 GL1CC (if appropriate)
86256 GL1TC (if appropriate)
86255 GL5CC (if appropriate)
86256 GL5TC (if appropriate)
86255 NCDCC (if appropriate)
86256 NCDTC (if appropriate)
86255 NFHCC (if appropriate)
86256 NIFTC (if appropriate)
86255 NFLCC (if appropriate)
86256 NMDIC (if appropriate)
84182 PC1BC (if appropriate)
86256 PC1TC (if appropriate)
86256 PC2TC (if appropriate)
84182 PCTBC (if appropriate)
86256 PCTTC (if appropriate)
86256 PDETC (if appropriate)
86255 SP5CC (if appropriate)
86256 SP5TC (if appropriate)
86255 SP7CC (if appropriate)
86256 SP7TC (if appropriate)
86255 T46CC (if appropriate)
86256 T46TC (if appropriate)
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| MDC2 | Movement, Autoimm/Paraneo, CSF | 94712-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 61513 | NMDA-R Ab CBA, CSF | 93502-3 |
| 61514 | AMPA-R Ab CBA, CSF | 93491-9 |
| 61515 | GABA-B-R Ab CBA, CSF | 93426-5 |
| 606959 | GRAF1 IFA, CSF | 96473-4 |
| 606965 | NIF IFA, CSF | 96490-8 |
| 606951 | IgLON5 CBA, CSF | 96481-7 |
| 615862 | AP3B2 IFA, CSF | 101907-4 |
| 615866 | Neurochondrin IFA, CSF | 101451-3 |
| 615874 | Septin-7 IFA, CSF | 101464-6 |
| 615870 | Septin-5 IFA, CSF | 101461-2 |
| 605971 | Ma2 Ab ELISA, CSF | 101867-0 |
| 620067 | PDE10A Ab IFA, CSF | 103842-1 |
| 616446 | TRIM46 Ab IFA, CSF | 103843-9 |
| 622118 | KLHL11-IgG CBA, CSF | 99073-9 |
| 623394 | mGluR5 Ab IFA, CSF | In Process |
| 605156 | GFAP IFA, CSF | 94360-5 |
| 606953 | ITPR1 IFA, CSF | 96467-6 |
| 64280 | LGI1-IgG CBA, CSF | 94288-8 |
| 64282 | CASPR2-IgG CBA, CSF | 94286-2 |
| 64927 | mGluR1 Ab IFA, CSF | 94361-3 |
| 64934 | DPPX Ab CBA, CSF | 94283-9 |
| 601997 | Movement Disorder Interp, CSF | 69048-7 |
| 89079 | AGNA-1, CSF | 90827-7 |
| 5906 | Amphiphysin Ab, CSF | 90815-2 |
| 3852 | ANNA-1, CSF | 44768-0 |
| 7472 | ANNA-2, CSF | 56959-0 |
| 21633 | ANNA-3, CSF | 90836-8 |
| 21650 | CRMP-5-IgG, CSF | 63216-6 |
| 3988 | PCA-1, CSF | 90841-8 |
| 21632 | PCA-2, CSF | 90843-4 |
| 21631 | PCA-Tr, CSF | 90845-9 |
| 21702 | GAD65 Ab Assay, CSF | 94359-7 |
| 618902 | IFA Notes | 48767-8 |